Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae661 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Ashley J Stoffers und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Children's Hospital of Philadelphia, Division of Endocrinology and Diabetes, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Fractures, Bone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, CHOP Research Institute.
Abstract (Originalsprache)
Context
Prior studies have demonstrated the safety and efficacy of zoledronic acid (ZA) to increase bone mineral density (BMD) in children. By contrast, the efficacy of ZA on fractures in the pediatric population remains uncertain.
Objective
To investigate the effect of ZA on fracture rate in a clinical cohort of children and young adults with skeletal fragility.
Methods
This retrospective cohort study, conducted at an academic medical center, included 102 individuals (65 male; 39 with primary and 63 with secondary skeletal fragility), aged 0 to 21 years, treated with ZA for skeletal fragility between 2010 and 2017. ZA was prescribed at discretion of the treating clinician using a standardized protocol. The primary outcome was change in annualized fracture rate. Secondary outcomes included long bone and spine fracture rates. Areal BMD was analyzed in a subset of individuals with dual energy x-ray absorptiometry (DXA) scans.
Results
The overall median fracture rate decreased from 0.6 (IQR 0.3-1.1) to 0 (IQR 0-0.4) fractures per year, P < .001, over a median treatment duration of 1.8 (IQR 0.6-3.0) years. Significant reductions in fracture rate were observed in both primary (1.0 [IQR 0.6-1.5] to 0.3 [IQR 0-0.6]) and secondary (0.5 [IQR 0.1-0.8] to 0 [IQR 0-0.3]) forms of skeletal fragility, P < .001 for both. Significant reductions in fracture rate persisted when limited to long bone or long bone plus spine fractures.
Conclusion
ZA treatment as a component of clinical care was associated with significant declines in fracture rate in this cohort of children and young adults with skeletal fragility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Children's Hospital of Philadelphia, Division of Endocrinology and Diabetes, Philadelphia, PA 19104, USA.
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Ashley J Stoffers, Michael A Levine
Förderung
- NIDDK NIH HHS
- NIH HHS
- CHOP Research Institute
- National Institutes of Health
Zitieren
APA
Stoffers, A. J., Mancilla, E. E., Levine, M. A., Mayer, M., Monk, H. M., Rosano, J., & Weber, D. R. (2025). Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae661
Vancouver
Stoffers AJ, Mancilla EE, Levine MA, Mayer M, Monk HM, Rosano J, et al. Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae661
BibTeX
@article{Stoffers2025,
author = {Stoffers, Ashley J and Mancilla, Edna E and Levine, Michael A and Mayer, Michael and Monk, Heather M and Rosano, Joseph and Weber, David R},
title = {Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae661}
}
EUVIMED